JP2011523052A - Glp−1受容体アゴニスト・バイオアッセイ - Google Patents

Glp−1受容体アゴニスト・バイオアッセイ Download PDF

Info

Publication number
JP2011523052A
JP2011523052A JP2011510592A JP2011510592A JP2011523052A JP 2011523052 A JP2011523052 A JP 2011523052A JP 2011510592 A JP2011510592 A JP 2011510592A JP 2011510592 A JP2011510592 A JP 2011510592A JP 2011523052 A JP2011523052 A JP 2011523052A
Authority
JP
Japan
Prior art keywords
glp
camp
sample
receptor agonist
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011510592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523052A5 (cg-RX-API-DMAC7.html
Inventor
ミチャリス・ニコラオウ
フレデリック・チャールズ・バンクロフト
ジョン・パトリック・ヘリッチ
アウン・ナイン・ルウィン
スワティ・グプタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of JP2011523052A publication Critical patent/JP2011523052A/ja
Publication of JP2011523052A5 publication Critical patent/JP2011523052A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
JP2011510592A 2008-05-23 2009-05-15 Glp−1受容体アゴニスト・バイオアッセイ Pending JP2011523052A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5584208P 2008-05-23 2008-05-23
US61/055,842 2008-05-23
PCT/US2009/044135 WO2009143014A1 (en) 2008-05-23 2009-05-15 Glp-1 receptor agonist bioassays

Publications (2)

Publication Number Publication Date
JP2011523052A true JP2011523052A (ja) 2011-08-04
JP2011523052A5 JP2011523052A5 (cg-RX-API-DMAC7.html) 2012-06-28

Family

ID=41202523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011510592A Pending JP2011523052A (ja) 2008-05-23 2009-05-15 Glp−1受容体アゴニスト・バイオアッセイ

Country Status (4)

Country Link
US (2) US8329419B2 (cg-RX-API-DMAC7.html)
EP (1) EP2288918A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011523052A (cg-RX-API-DMAC7.html)
WO (1) WO2009143014A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Glp−1アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US20120048003A1 (en) * 2010-08-24 2012-03-01 GOLDEN PRODUCTS LLC, Limited Liability Company Vitamin assay methods
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US20130183696A1 (en) * 2010-09-15 2013-07-18 Constance Neely Wilson Methods of use and kit for measurement of lipopolysaccharide with a time resolved fluorescence based assay
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN103424496B (zh) * 2012-05-24 2015-02-18 山东绿叶制药有限公司 一种测定痕量艾塞那肽的方法
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
EP3517122A1 (en) 2013-04-03 2019-07-31 Sanofi Treatment of diabetes mellitus by long-acting formulations of insulins
CN103344764B (zh) * 2013-06-19 2014-11-26 天津美德太平洋科技有限公司 胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
CN103408669B (zh) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白,及其制备方法和用途
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104569419B (zh) * 2014-09-23 2016-07-06 范列英 一种检测人血液glp-1总含量的化学发光免疫分析法试剂盒
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
CN109475568B (zh) 2016-05-06 2026-07-17 Ionis制药公司 Glp-1受体配体部分缀合的寡核苷酸及其用途
MA55504A (fr) 2019-04-01 2022-02-09 Novo Nordisk As Anticorps dirigés contre le liraglutide et leur utilisation
KR20230125802A (ko) * 2020-12-11 2023-08-29 아이피2아이피오 이노베이션스 리미티드 신규 화합물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005527A2 (en) * 2006-07-06 2008-01-10 Amylin Pharmaceuticals, Inc. Glucagon-like peptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672128B1 (fr) 1991-01-28 1995-08-18 Cis Bio Int Procede de mesure de la luminescence emise dans un dosage par luminescence.
FR2810406B1 (fr) 2000-06-15 2002-09-20 Cis Bio Int Nouveaux cryptates de terre rare peu sensibles a l'extinction de fluorescence
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005527A2 (en) * 2006-07-06 2008-01-10 Amylin Pharmaceuticals, Inc. Glucagon-like peptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013025518; TECAN アプリケーションノート , 2007 *

Also Published As

Publication number Publication date
US20130089878A1 (en) 2013-04-11
WO2009143014A1 (en) 2009-11-26
US8329419B2 (en) 2012-12-11
EP2288918A1 (en) 2011-03-02
US20110097751A1 (en) 2011-04-28
US8603761B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
US8329419B2 (en) GLP-1 receptor agonist bioassays
Varndell et al. Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry.
JP7610535B2 (ja) セリアック病の診断、スクリーニング、および治療のための患者由来腸オルガノイドの使用
JP5281594B2 (ja) グルカゴン様ペプチド−2、ならびにその治療への使用
Bhat et al. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties
Hartmann et al. Structure, measurement, and secretion of human glucagon-like peptide-2
US7888317B2 (en) Glucagon-like peptide-2 and its therapeutic use
Windeløv et al. Why is it so difficult to measure glucagon-like peptide-1 in a mouse?
EP0906338B1 (en) Glucagon-like peptide-2 analogs
US5789379A (en) Glucagon-like peptide-2 analogs
US7781401B2 (en) Glucagon-like peptide-2 analogs
EP0914341B1 (en) Antagonists of intestinotrophic glp-2 peptides
JP2011523052A5 (cg-RX-API-DMAC7.html)
TW200922615A (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
Sebokova et al. Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency
Pederson et al. Discovery of gastric inhibitory polypeptide and its subsequent fate: Personal reflections
CN107201342A (zh) 一种用于筛选肽类和非肽类glp‑1类似物的细胞株及其制备方法与应用
Kim et al. Synthesis, bioactivity and specificity of glucagon-like peptide-1 (7–37)/polymer conjugate to isolated rat islets
WO2024133236A2 (en) Peptide conjugates for labelling endogenous gipr and glp-1r
Janabi Proinsulin C-peptide-mediated signalling and the search for its receptor
Van Noorden et al. Regulatory peptide immunocytochemistry at light-and electron microscopical levels
HK1153482A (en) Glucagon-like peptide-2 derivatives and their therapeutic use
HK1149720A (en) Glucagon-like peptide-2 and its therapeutic use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101122

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130228

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130826

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130902

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140225